Log In
person
Longeveron Inc
LGVN
summarize
2 total product lines
calendar_month
Revenue as of 12/31/2023
| Reporting Segmentarrow_drop_up | Product Line | Amount (USD) | Percentage |
|---|---|---|---|
| keyboard_arrow_right | Reporting Segment & Product Line | Amount (USD) | Percentage |
| Cellular Therapies |
Pharmaceutical Contract Developer and Manufacturing Organizations (CDMOs)
These companies, commonly known as CDMOs, provide specialized services for drug manufacturers, such as drug discovery, research, development, and manufacturing.
|
668,000 | 94.22% |
| Cellular Therapies |
Pre-Revenue Pharmaceuticals
These companies research and develop pharmaceuticals, but do not generate significant revenue. They may eventually market or manufacture their products (pending regulatory approval) or generate revenue through royalties or other means.
|
41,000 | 5.78% |
| keyboard_arrow_down |
Cellular Therapies
Pharmaceutical Contract Developer and Manufacturing Organizations (CDMOs)
|
668,000 | 94.22% |
| keyboard_arrow_right |
These companies, commonly known as CDMOs, provide specialized services for drug manufacturers, such as drug discovery, research, development, and manufacturing.
|
||
| keyboard_arrow_down |
Cellular Therapies
Pre-Revenue Pharmaceuticals
|
41,000 | 5.78% |
| keyboard_arrow_right |
These companies research and develop pharmaceuticals, but do not generate significant revenue. They may eventually market or manufacture their products (pending regulatory approval) or generate revenue through royalties or other means.
|
||